Douglas B. Johnson

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 75 papers. Top paper: “Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma”.

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Cancer Cell(2020)10.1016/j.ccell.2020.08.005

N/A

9.5DataRank · unranked

393 citations

Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodríguez, Petra Ross‐Macdonald, Megan Wind‐Rotolo +31 more

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0856

N/A

8.5DataRank · unranked

279 citations

Wouter C. Meijers, Margaret L. Axelrod, Nana-Ama A.S. Anang, Elles M. Screever, Elizabeth C. Wescott +22 more

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Annals of Oncology(2021)10.1016/j.annonc.2021.02.024

N/A

6.8DataRank · unranked

328 citations

Ali Raza Khaki, Trisha M. Wise‐Draper, Benjamin French, Conor Hennessy, Chih–Yuan Hsu +95 more

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02498-y

N/A

4.8DataRank · unranked

171 citations

Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia +28 more

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

Annals of Oncology(2020)10.1016/j.annonc.2020.04.471

N/A

3.5DataRank · unranked

110 citations

Alexander N. Shoushtari, D Chauhan, David Palmieri, Belinda Lee, Maartje W. Rohaan +20 more

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

OncoImmunology(2021)10.1080/2162402x.2021.1875639

N/A

2.2DataRank · unranked

63 citations

Ben McGuigan, Sunandana Chandra, Sarah E. Fenton, Akansha Chowdhary, Lucy Boyce Kennedy +14 more

Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome

Science Advances(2020)10.1126/sciadv.abb3461

N/A

2.0DataRank · unranked

60 citations

Gyulnara G. Kasumova, William A. Michaud, Jessica Cintolo-Gonzalez, Marta Díaz-Martínez, Jacqueline Ohmura +13 more

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Cancer Cell(2021)10.1016/j.ccell.2020.11.015

N/A

1.9DataRank · unranked

53 citations

Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodriguez, Petra Ross-Macdonald, Megan Wind-Rotolo +31 more

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS -mutant Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3872

N/A

1.6DataRank · unranked

44 citations

Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow +10 more

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

JAMA Oncology(2022)10.1001/jamaoncol.2022.5357

N/A

1.5DataRank · unranked

63 citations

Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati, Chih–Yuan Hsu +95 more

Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study

The Oncologist(2021)10.1002/onco.13795

N/A

1.5DataRank · unranked

43 citations

Douglas B. Johnson, Ryan J. Sullivan, R. Amaria, Keith T. Flaherty, Jeffrey A. Sosman +2 more

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

Molecular Cancer(2021)10.1186/s12943-021-01366-y

N/A

1.4DataRank · unranked

39 citations

Nabil Saleh, Jinming Yang, Caroline A. Nebhan, Anna E. Vilgelm, E. Premkumar Reddy +7 more

Immune checkpoint inhibitor-associated myocarditis: a novel risk score

European Heart Journal(2025)10.1093/eurheartj/ehaf315

N/A

1.1DataRank · unranked

47 citations

Charles Dolladille, Benay Ozbay, Adrien Procureur, Stéphane Éderhy, Nicolas L. Palaskas +92 more

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.0051

N/A

0.832DataRank · unranked

256 citations

Rebecca Johnson, Aleigha Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova +15 more

Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis

Circulation(2023)10.1161/circulationaha.123.062405

N/A

0.753DataRank · unranked

150 citations

Markus Heckmann, Guillaume Bailly, Daniel Finke, Adrien Procureur, John R. Power +58 more

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000331

N/A

0.725DataRank · unranked

125 citations

Kristina Navrazhina, Fei Ding, Roma Bhatia, Katy K. Tsai, Kelly Abbate +23 more

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research

The Lancet Oncology(2020)10.1016/s1470-2045(20)30107-8

N/A

0.709DataRank · unranked

112 citations

Kerry L. Reynolds, Ryan J. Sullivan, Justin M. Balko, James R. Patrinely, Laura C. Cappelli +3 more

The State of Melanoma: Emergent Challenges and Opportunities

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4092

N/A

0.705DataRank · unranked

109 citations

Clara Curiel‐Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre‐Ghiso +31 more

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.03.011

N/A

0.703DataRank · unranked

15 citations

Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel‐Wahab +25 more

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3443

N/A

0.678DataRank · unranked

91 citations

Fengmin Zhao, Marcus Smith Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright +15 more

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000451

N/A

0.650DataRank · unranked

75 citations

Daniel Wang, Alexandra Coromilas, Melissa Lumish, Tianqi Chen, Anita Giobbie‐Hurder +4 more

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003066

N/A

0.628DataRank · unranked

65 citations

Allison Betof Warner, Farzana Y. Zaman, Andrew Haydon, Prachi Bhave, Anna K. Dewan +20 more

Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy

British Journal of Clinical Pharmacology(2020)10.1111/bcp.14433

N/A

0.606DataRank · unranked

56 citations

Renee McAlister, Justin M. Balko, Douglas B. Johnson, Javid J. Moslehi, Andrew Gibson +2 more

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms

Journal of bone oncology(2023)10.1016/j.jbo.2023.100505

N/A

0.574DataRank · unranked

45 citations

Douglas B. Johnson, Rachelle W. Johnson, Gwenyth J. Joseph

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

Nature Communications(2024)10.1038/s41467-023-44512-4

N/A

0.533DataRank · unranked

34 citations

Rohit Thummalapalli, Michael J. Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam +28 more

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma

Cancer Cell(2025)10.1016/j.ccell.2025.01.009

N/A

0.524DataRank · unranked

32 citations

Mouadh Benamar, Jihye Park, Haley E. Sax, Giacomo Oliveira, Alice Bosma-Moody +10 more

Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction

The Journal of Clinical Endocrinology & Metabolism(2022)10.1210/clinem/dgac689

N/A

0.510DataRank · unranked

29 citations

Douglas B. Johnson, J. J. Wright

Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data

JCO Clinical Cancer Informatics(2024)10.1200/cci.23.00207

N/A

0.500DataRank · unranked

27 citations

Kathleen F. Mittendorf, Zoltán Kiss, Michele L. Lenoue-Newton, Pablo Napan-Molina, Protiva Rahman +17 more

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-007675

N/A

0.500DataRank · unranked

27 citations

Yevgeniy R. Semenov, Allireza Alloo, Daniel Q. Bach, Allison Betof Warner, Amina Bougrine +36 more

Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction

JACC CardioOncology(2025)10.1016/j.jaccao.2025.01.020

N/A

0.470DataRank · unranked

22 citations

Charles Dolladille, Anjali Rao, Nicolas L. Palaskas, Anita Deswal, Lorenz Lehmann +51 more

Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

Cancer Immunology Research(2016)10.1158/2326-6066.cir-15-0281

N/A

0.464DataRank · unranked

21 citations

Richard Joseph, Chengwei Peng, Fei Ye, Shilin Zhao, Igor Puzanov +3 more

Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.13727

N/A

0.425DataRank · unranked

16 citations

Marc Machaalani, Razane El Hajj Chehade, Amin H. Nassar, Rashad Nawfal, Michael P. Manos +20 more

Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer

medRxiv(2020)10.1101/2020.04.29.20085738

N/A

0.406DataRank · unranked

14 citations

Kelli L. Boyd, Paula I. González-Ericsson, Cindy Lowe, Hunter M. Brown, Robert Hoffman +12 more

Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity

medRxiv(2024)10.1101/2024.06.02.24308336

N/A

0.383DataRank · unranked

6 citations

Charles Dolladille, Adriel Procureur, Stéphane Éderhy, Nicolas L. Palaskas, Lorenz Lehmann +47 more

Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)

Journal of Translational Medicine(2023)10.1186/s12967-023-04329-7

N/A

0.373DataRank · unranked

11 citations

Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua Brody, Leisha A. Emens +19 more

Immune Checkpoint Inhibitors’ Effects on Calcified Aortic Plaques in Melanoma Survivors

JACC CardioOncology(2023)10.1016/j.jaccao.2023.05.005

N/A

0.345DataRank · unranked

9 citations

Sangeeta Nair, James G. Terry, Shi Huang, J. Jeffrey Carr, Javid J. Moslehi +4 more

Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9591

N/A

0.292DataRank · unranked

6 citations

Aleigha Lawless, Rachel Woodford, Faisal Fa’ak, Asha Tipirneni, James R. Patrinely +11 more

Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors

The Oncologist(2023)10.1093/oncolo/oyad219

N/A

0.292DataRank · unranked

6 citations

Seungyeon Jung, Fei Ye, Lili Sun, Douglas B. Johnson, Rajiv Agarwal +1 more

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-011865

N/A

0.292DataRank · unranked

6 citations

Yee-Ming Melody Cheung, Cherie Chiang, Emily J. Gallagher, Ole‐Petter R. Hamnvik, Jennifer S. Mammen +32 more

Interoperability of phenome-wide multimorbidity patterns: a comparative study of two large-scale EHR systems

medRxiv(2024)10.1101/2024.03.28.24305045

N/A

0.269DataRank · unranked

5 citations

Tess Vessels, Karmel W. Choi, Siwei Zhang, Yajing Li, Lide Han +21 more

Plasma-derived exosomal analysis and deconvolution enables prediction and tracking of melanoma checkpoint blockade response

bioRxiv (Cold Spring Harbor Laboratory)(2019)10.1101/809699

N/A

0.219DataRank · unranked

2 citations

Gyulnara G. Kasumova, William A. Michaud, Jessica Cintolo-Gonzales, Marta Díaz Martínez, Jacqueline Ohmura +12 more

Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma

Cancer(2020)10.1002/cncr.32984

N/A

0DataRank · unranked

40 citations

Laura X. Baker, Elizabeth J. Davis, Haocan Song, Fei Ye, Douglas B. Johnson +1 more

Solid organ transplant rejection associated with immune-checkpoint inhibitors

Annals of Oncology(2020)10.1016/j.annonc.2020.01.012

N/A

0DataRank · unranked

17 citations

Lee S. Nguyen, Ali Manouchehri, Bénédicte Lebrun‐Vignes, Javid J. Moslehi, Douglas B. Johnson +3 more

Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy

Cancer Immunology Research(2020)10.1158/2326-6066.cir-19-0986

N/A

0DataRank · unranked

65 citations

Haocan Song, Fei Ye, Javid J. Moslehi, Justin M. Balko, Joe‐Elie Salem +2 more

Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007736

N/A

0DataRank · unranked

29 citations

Brandie C. Taylor, Margaret L. Axelrod, Xiaopeng Sun, Lindsey N. Guerin, Paula I. González-Ericsson +9 more

Multi-organ landscape of therapy-resistant melanoma

Nature Medicine(2023)10.1038/s41591-023-02304-9

N/A

0DataRank · unranked

31 citations

Prashanthi Dharanipragada, Shirley H. Lomeli, Yan Wang, Xiao Zhang, Zhentao Yang +9 more

Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity

Expert Review of Anticancer Therapy(2023)10.1080/14737140.2023.2215435

N/A

0DataRank · unranked

5 citations

Thomas J. Gracie, Douglas B. Johnson, Catherine C. Fahey

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

medRxiv(2023)10.1101/2023.05.15.23289680

N/A

0DataRank · unranked

4 citations

Rohit Thummalapalli, Michael J. Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam +23 more

Data from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

(2023)10.1158/1078-0432.c.6532311

N/A

0DataRank · unranked

0 citations

Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow +10 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Advanced Melanoma

Hematology/Oncology Clinics of North America(2020)10.1016/j.hoc.2020.09.005

N/A

0DataRank · unranked

16 citations

April K.S. Salama, Douglas B. Johnson, Alexandra M. Haugh

Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-1895

N/A

0DataRank · unranked

48 citations

Sheau‐Chiann Chen, Emily Murray, Christopher Andrew Johnson, Holly Crandall, Jamye F. O’Neal +14 more

67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity

Annals of Oncology(2024)10.1016/j.annonc.2024.08.075

N/A

0DataRank · unranked

0 citations

Zoe Quandt, Ashis Saha, Lifen Yao, P. Midda, Yaomin Xu +15 more

Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.10.011

N/A

0DataRank · unranked

0 citations

Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel‐Wahab +25 more

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy

Journal of Clinical Investigation(2020)10.1172/jci133055

N/A

0DataRank · unranked

251 citations

Kathy S. Evans, Nicholas C. DeVito, Michael P. Plebanek, Michael Sturdivant, Luke P. Wachsmuth +10 more

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade

OncoImmunology(2025)10.1080/2162402x.2025.2494433

N/A

0DataRank · unranked

15 citations

Rebecca Irlmeier, Xue Bai, Can Cui, Fei Ye, Hannah Burnette +5 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors

Immunity(2025)10.1016/j.immuni.2025.10.001

N/A

0DataRank · unranked

3 citations

Shiyue Yang, Zhentao Yang, Jianfeng Fan, Shirley H. Lomeli, Prashanthi Dharanipragada +12 more

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States

UNC Libraries(2025)10.17615/bc35-y591

N/A

0DataRank · unranked

0 citations

Praful Ravi, Robert A. Baiocchi, Noha Abdel‐Wahab, Swetha Kambhampati, Talal El Zarif +25 more

Evaluating the impact of immune checkpoint inhibitors on liver steatosis and function: a retrospective cohort analysis

Frontiers in Oncology(2025)10.3389/fonc.2025.1683982

N/A

0DataRank · unranked

0 citations

Jessica Quintos Day, Run Fan, Fei Ye, Virginia Planz, Douglas B. Johnson +1 more

Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression

medRxiv(2025)10.1101/2025.10.06.25337175

N/A

0DataRank · unranked

0 citations

Nagendra Sastry Yarla, Kaylee Villareal, Y‐Van Nguyen, Linda Cao, Ernesto Pena Calderin +9 more

Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3720

N/A

0DataRank · unranked

6 citations

Nicolas Coudray, George Jour, Milad Ibrahim, Irineu Illa-Bochaca, Shi Qiu +8 more

Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies

Circulation Research(2021)10.1161/circresaha.120.315894

N/A

0DataRank · unranked

129 citations

Olalekan O. Oluwole, Douglas B. Johnson, Nina Shah, Joe‐Elie Salem, Katy K. Tsai +2 more

Characterizing toxicities, body composition, and health-related quality of life (HRQoL) among long-term survivors treated with anti-PD-1.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e15158

N/A

0DataRank · unranked

0 citations

Arissa Young, Henry T. Quach, Grant R. Williams, Fei Ye, Run Fan +8 more

A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis

The Oncologist(2020)10.1002/onco.13608

N/A

0DataRank · unranked

4 citations

Elisa Funck‐Brentano, Khang Nguyen, Suthee Rapisuwon, Joe‐Elie Salem, Geoffrey T. Gibney +3 more

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Clinical Hematology International(2021)10.2991/chi.k.210718.001

N/A

0DataRank · unranked

18 citations

Ameet Patel, Shi Huang, Yan Su, Kimberly B. Dahlman, Kelsey Tomasek +9 more

T cells specific for α-myosin drive immunotherapy-related myocarditis

Nature(2022)10.1038/s41586-022-05432-3

N/A

0DataRank · unranked

328 citations

Wouter C. Meijers, Elles M. Screever, Juan Qin, Mary Grace Carroll, Xiaopeng Sun +21 more

The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer

BioDrugs(2020)10.1007/s40259-020-00428-9

N/A

0DataRank · unranked

25 citations

Anna K. Dewan, Douglas B. Johnson, James R. Patrinely

Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis

Science Translational Medicine(2022)10.1126/scitranslmed.abo1981

N/A

0DataRank · unranked

57 citations

Cheng‐Cao Sun, Yajuan Li, Juan Qin, Kaushik Amancherla, Ying Jing +26 more

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

Oncogenesis(2020)10.1038/s41389-020-0228-x

N/A

0DataRank · unranked

28 citations

Keshab R. Parajuli, Suresh Chava, Rudradip Pattanayak, Deborah L. Della Manna, Deepmala Shrestha +5 more

Balancing Cancer Immunotherapy Efficacy and Toxicity

The Journal of Allergy and Clinical Immunology In Practice(2020)10.1016/j.jaip.2020.06.028

N/A

0DataRank · unranked

40 citations

Baruch D. Jakubovic, V. Sibaud, Meghan E. Sise, Douglas B. Johnson

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients

npj Precision Oncology(2022)10.1038/s41698-021-00249-1

N/A

0DataRank · unranked

11 citations

Sheau‐Chiann Chen, Gregory D. Ayers, Caroline A. Nebhan, Joseph T. Roland, Vivian Weiß +3 more

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors

medRxiv(2022)10.1101/2022.02.17.22271120

N/A

0DataRank · unranked

1 citations

Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo‐Jack +24 more

Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2508

N/A

0DataRank · unranked

0 citations

Melissa Moey, Xiao-Wei Cherie Tan, Mehak M Laharwal, Vanessa Hill, Nagabhishek Moka +6 more

Reply to S. Rossi et al and P. Palassin et al

日本体育学会大会号(2022)10.1200/jco.22.01928

N/A

0DataRank · unranked

0 citations

Douglas B. Johnson, Javid J. Moslehi, Elad Sharon, Abdul Rafeh Naqash